Home » Therapeutic Antibody » Antibody Drug Reagent Service » Pseudovirus Neutralization Assay Services for SARS-CoV-2

Pseudovirus Neutralization Assay Services for SARS-CoV-2

Entry of Coronavirus into host cells is mediated by the trimeric transmembrane spike (S) glycoprotein (Fig. 1). S glycoprotein is surface-exposed and mediates entry into the host cells by binding to human angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 receptor, which makes S glycoprotein the major target of neutralizing antibodies and the focus of therapeutic and vaccine design.

A model that simulates the infection of the SARS-CoV-2 is designed by replacing the envelope glycoprotein in the lentivirus vector with the S protein. Neutralizing antibodies blocking S protein (Fig. 2). and receptor binding could prevent the virus from infecting host cells. By detecting the luminescence of target cells, it is possible to screen or verify the activity of the neutralizing antibody.

GenScript ProBio provides not only assay service but also neutralization kit, meeting all your needs for both research and industry application.

  • Fig.1 Pseudovirus with S glycoprotein as the envelope protein

  • Fig.2 Neutralizing antibodies preventing the pseudovirus from entering host cells

Workflow of Neutralization Assay

Service Highlights

  • Virus entry assay model:
    A viral entry model, mimicking physiological entry mechanism.
  • Variants of SARS-CoV-2 available
    Extensible system, SARS-CoV-1 and multiple variants available; cutomized variants available.
  • High specificity:
    Ability to specifically screen drugs blocking pseudovirus entry.
  • High sensitivity:
    S/N > 100, activities of different candidates can be clearly distinguished.
  • Fast delivery:
    1-3 weeks to get results

Service Details

Starting materials
  • ≥ 100 μg neutralizing antibody for single dose screening, or ≥ 200 μg for dose-response assay
  • supernatant with antibody ≥ 1 μg/mL, more than ≥ 500 μL (Optimization is needed for different culture media)
  • Serum samples from immunized animals. Human samples should be tested with pseudovirus neutralization kit
  • Small molecules, peptides or other candidate samples inhibiting virus entry
  • Pseudovirus and target cells for infection are provided by GenScript

Delivery: Neutralization assay report

QC standard: S/N ≥ 100

Turnaround time:  1-3 weeks*

*TAT may extend due to the number of samples.

Pseudovirus Neutralization Assay Kit

Product Cat. No. name Deliverable TAT
Luciferase reporter kit SC2087A SARS-CoV-2 Pseudovirus Neutralization Assay kit_Luc reporter

    Components:

  • R Pseudovirus:
  • 1 vial of Luc reporter or 2 vials of GFP reporter for a 96-well plate
  • 10^7-8 IFU
  • R Target cell:
  • 2 vials for a 96-well plate
  • 2 × 10^6 cells/vial (proliferation-incompetent)
  • R Positive neutralizing antibody for 1 dose curve:
  • for 1 dose curve

Wild type:4 weeks

Mutant type:Quote

SC2087B SARS-CoV-2 D614G Pseudovirus Neutralization Assay kit_Luc reporter
SC2087C SARS-CoV-2 V367F Pseudovirus Neutralization Assay kit _Luc reporter
SC2087D SARS-CoV-2 W436R Pseudovirus Neutralization Assay kit _Luc reporter
SC2087E SARS-CoV-2 D364Y Pseudovirus Neutralization Assay kit _Luc reporter
GFP reporter kit SC2087F SARS-CoV-2 Pseudovirus Neutralization Assay kit _GFP reporter
SC2087G SARS-CoV-2 D614G Pseudovirus Neutralization Assay kit _ GFP reporter
SC2087H SARS-CoV-2 V367F Pseudovirus Neutralization Assay kit _ GFP reporter
SC2087I SARS-CoV-2 W436R Pseudovirus Neutralization Assay kit _ GFP reporter
SC2087J SARS-CoV-2 D364Y Pseudovirus Neutralization Assay kit _ GFP reporter

* Components can be purchased separately. Please Quote.

Service Highlights

  • Virus entry assay model:
    A viral entry model, consistent with the physiological entry mechanism
  • Variants of SARS-CoV-2 available:
    Extensible system, SARS-CoV-1 and multiple variants available; cutomized variants available
  • High specificity:
    Ability to specifically screen drugs blocking pseudovirus entry
  • High sensitivity:
    S/N as high as about 100, activities of different candidates can be clearly distinguished
  • Ready to use:
    Save time on condition optimization
  • Free from sample degeneration:
    Especially for serum samples
  • Pseudovirus neutralization assay

  • Live virus neutralization assay

  • Figure 1. Comparable IC50 values of live virus and pseudovirus neutralization assay using the same sample.

  • Neutralization by ACE2-Fc

    Figure 2. Positive control ACE2-Fc can effectively inhibit pseudovirus entry in a dose-dependent manner

  • Consistent IC50 in independent tests

    Figure 3. Antibody candidates were screened for their ability to inhibit pseudovirus entry.

  • Neutralization by immunized mice serum

    Figure 4. Immunized mouse serum can effectively inhibit pseudovirus entry